loading...

EORTC Quality of Life - Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ-CIPN20)

EORTC Quality of Life Group

ProQolid

Basic description

Published in 2005

Authors

EORTC Quality of Life Group

Copyright
QLQ-CIPN20 © EORTC Study Group on Quality of life, 2003. All rights reserved.
Objective
To elicit patients' experience of symptoms and functional limitations related to chemotherapy-induced peripheral neuropathy
Therapeutic area
  • Neoplasms
  • Nervous System Diseases
Therapeutic indication
  • Generic for Neoplasms
  • Generic for Nervous System Diseases
Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English
Translations
40 translation(s)
Bibliographic reference(s) of the original questionnaire

Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R; EORTC Quality of Life Group. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005 May;41(8):1135-9 (PubMed abstract)

Kieffer JM, Postma TJ, van de Poll-Franse L, Mols F, Heimans JJ, Cavaletti G, Aaronson NK; CI-PeriNomS Group. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). QualLife Res. 2017 Jun 20 [Epub ahead of print] (PubMed Abstract)

Knoerl R, Gray E, Stricker C, Mitchell SA, Kippe K, Smith G, Dudley WN, Lavoie Smith EM.  Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2017 Jun 2 (PubMed Abstract)

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us